ArticleInternational ophthalmology2021
Combined Ab interno viscocanaloplasty (ABiC) in open-angle glaucoma: 12-month outcomes.
Article in International ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 20 citations in OpenAlex.
- Combined Phacoemulsification and STREAMLINE Surgical System Canal of Schlemm Transluminal Dilation in Eyes of Hispanic Patients with Mild to Moderate Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2023Trial
- Canaloplasty and Trabeculotomy Combined with Phacoemulsification for Glaucoma: 12-Month Results of the GEMINI Study.Clinical ophthalmology (Auckland, N.Z.) · 2022Trial
- Multicentre study comparing ab-interno canaloplasty and trabecular micro-bypass stent in primary open-angle glaucoma.Eye (London, England) · 2026Article
- Real-World Multicenter Evaluation of Ab-Interno Canaloplasty Using a New Canaloplasty Device with and without Concomitant Phacoemulsification in Uncontrolled Open-Angle Glaucoma: 12-Month Outcomes.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Incidence and risk factors for early transient intraocular pressure elevation after penetrating canaloplasty in patients with glaucoma.BMC ophthalmology · 2025Article
- Visual Function After Schlemm's Canal-Based MIGS.Journal of clinical medicine · 2025Review
- Real-World Outcomes of Combined Phacoemulsification and STREAMLINEClinical ophthalmology (Auckland, N.Z.) · 2025Article
- Comparative effectiveness and safety of GATT with or without ABiC in patients with open-angle glaucoma.Frontiers in medicine · 2025Article
- Efficacy and safety of combined Kahook Dual Blade goniotomy with phacoemulsification in Chinese patients with primary open angle glaucoma.International journal of ophthalmology · 2025Article
- Historical and Contemporary Debates in Schlemm's Canal-Based MIGS.Journal of clinical medicine · 2024Review
- Consistency in Standalone Canaloplasty Outcomes Using the iTrack Microcatheter.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Clinical outcomes of canaloplasty via an ab-interno surgical technique using the iTrack device: a narrative review.International ophthalmology · 2023Review
- Incidence and risk factors of early transient intraocular pressure elevation after canaloplasty for primary open-angle glaucoma.Journal of Zhejiang University. Science. B · 2023Article
- Minimally Invasive Glaucoma Surgery: Safety of Individual Devices.Journal of clinical medicine · 2022Review
- Interim Analysis of STREAMLINEClinical ophthalmology (Auckland, N.Z.) · 2022Article
- The Impact of Interventional Glaucoma with and without Cataract Surgery in Early Open-angle Glaucoma: 24-month Results with a New Canaloplasty Device.Journal of current glaucoma practiceArticle
- A Review of Canaloplasty in the Treatment and Management of Glaucoma.Journal of current glaucoma practiceReview
- Viscodilation of Schlemm's Canal Combined with Goniectomy Using a 30 G Needle (Visco-Bent Ab Interno Needle Goniectomy).Journal of current glaucoma practiceArticle
- Canaloplasty in the spotlight: surgical alternatives and future perspectives.Romanian journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to analyse the safety profile and efficacy of ab interno viscocanaloplasty (ABiC) through to 12 months post-operatively.
methodsIn this retrospective study, the medical records of all patients who underwent ABiC between September 2015 and December 2019 were analysed. Complete success was defined as a 12-month reduction in intraocular pressure (IOP) ≥ 20% from baseline with no concomitant medications. Qualified success criteria were identical, with no more medications than at baseline.
resultsIn all, 54 eyes of 41 patients were analysed. Mean IOP decreased from 23.6 ± 7.4 mmHg preoperatively to 14.2 ± 2.9 mmHg (-39.8%; p < 0.001) after 12 months. Concomitantly, the number of anti-glaucoma treatment dropped from 2.9 ± 1.0 to 0.6 ± 1.1 (-79.3%; p < 0.001). Amongst patients with a baseline MD < -12.0 dBs, mean IOP decreased from 22.8 ± 9.8 mmHg to 13.8 ± 4.4 mmHg (p = 0.049), with a concomitant reduction of medications from 2.8 ± 1.3 to 1.2 ± 1.3 (p < 0.001). Complete success at 12 months was achieved in 46% of eyes, and qualified success was achieved in 65% of eyes. Amongst eyes with a baseline MD < -12.0 dBs, 50% achieved complete success, and 83.3% achieved qualified success. A total of 19 eyes (35.2%) were considered surgical failure, all due to uncontrolled IOP. Of them, 7 eyes (13.0%) required further filtering surgery. Twelve post-operative adverse events were observed, with early post-operative IOP spikes being the most common (22.2%).
conclusionsABIC achieved a statistically significant reduction in IOP and anti-glaucoma medications through 12 months, while maintaining a favourable safety profile in mild-to-severe open-angle glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.